| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
4,391 |
4,089 |
$296K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,063 |
4,682 |
$267K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
2,924 |
2,840 |
$257K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
3,407 |
3,359 |
$216K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,186 |
1,871 |
$57K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,098 |
557 |
$13K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
459 |
398 |
$13K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,018 |
981 |
$12K |
| 87428 |
|
398 |
385 |
$8K |
| 99000 |
|
3,687 |
3,382 |
$8K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
376 |
358 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
123 |
123 |
$3K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
62 |
62 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
30 |
30 |
$2K |
| 81002 |
|
681 |
667 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
64 |
64 |
$200.99 |
| 81025 |
|
27 |
26 |
$178.25 |
| 87210 |
|
56 |
52 |
$163.88 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
12 |
12 |
$11.78 |
| 99051 |
|
14 |
12 |
$0.00 |